Vor Biopharma Stock Analysis
| VOR Stock | USD 15.90 0.38 2.45% |
VOR is currently aligned with model with Market Value of 15.9 and Intrinsic Value of 15.47. The framework below evaluates VOR by comparing modeled intrinsic value to current market pricing. VOR reports negative return on equity, directing analytical focus toward capital allocation efficiency and the trajectory of shareholder value.
VOR holds a debt-to-equity ratio of 0.24 relative to health care peers. Comparing Vor Biopharma's leverage to its own 5-year average reveals whether the current capital structure is within historical norms or stretched. Asset vs Debt
Equity vs Debt
Vor Biopharma |
Investor Insights and Alerts
| Vor Biopharma is way too risky over 90 days horizon | |
| Vor Biopharma appears to be risky and price may revert if volatility continues | |
| Vor Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Reported Net Loss for the year was -$695.98 million with profit before taxes, overhead, and interest of . | |
| Vor Biopharma has about $151.09 million in cash as of latest reporting with -$142.71 million of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97. |
Market Capitalization
Vor Biopharma enters market cap screens as a small-cap name with total equity value near $718.55 million across health care companies. The broader capitalization picture also reflects enterprise value near $266.83 million, operating in the Health Care industry, and about 48.85 million shares outstanding.Technical Drivers
As of the 6th of May, Vor Biopharma maintains a quoted price of 15.90 per share. Short-term indicators show Coefficient Of Variation of 931.1, semi deviation of 4.29, and Risk Adjusted Performance of 0.1117. The model measures trend continuation and reversal probability using historical patterns. Comparative analytics measure deviation from sector averages.Price Movement Analysis - Bollinger Bands
This analysis covers thirty-eight data points across the selected time horizon. Bollinger Bands frame Vor Biopharma price range using a moving average and volatility bands. Movement toward the lower band may indicate short-term downside pressure, while approaches to the upper band can reflect resistance levels or momentum continuation.
Insider Trading Activities
The analytical value in Vor Biopharma's insider filings lies in transaction clustering, trade size, and timing relative to price movements rather than any single filing. The goal is to tell routine pay-related sales apart from trades that reflect genuine conviction.
Outstanding Bonds
Outstanding bonds linked to Vor Biopharma can tell investors a great deal about how the company finances itself beyond common equity markets. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.
| VOYA FINL INC Corp BondUS929089AB68 | View | |
| US929089AG55 Corp BondUS929089AG55 | View | |
| VOYA FINL INC Corp BondUS929089AF72 | View | |
| VOYA FINL INC Corp BondUS929089AC42 | View | |
| VNO 215 01 JUN 26 Corp BondUS929043AK39 | View | |
| VNO 34 01 JUN 31 Corp BondUS929043AL12 | View |
Predictive Daily Indicators
Daily signals in Vor Biopharma help active traders track momentum, reversals, and volume pressure during the session. The key question is whether the signal helps manage exposure in real time, not whether it predicts every tick.
Forecast Models
Forecasting applied to Vor Biopharma learns from price structure, volatility patterns, and trend strength rather than commentary alone. Financial data rarely stays stable for long, so the model is best used as a probability tool, not a price promise.Debt to Cash Allocation
Tracking debt and cash allocation over time can show when Vor Biopharma is prioritizing expansion, refinancing, or capital return.
Total debt stands at approximately $3 million with debt to equity (D/E) ratio of 0.24. Vor Biopharma has a current ratio of 12.69, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt serves as one financing mechanism for Vor Biopharma, though the impact on returns depends on execution and market conditions. Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Vor Biopharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Vor Biopharma, which in turn will lower the firm's financial flexibility.Corporate Bonds Issued
Stock Analysis Methodology
If Vor Biopharma fundamentals are improving, the diagnostic should show it through margins, leverage, and cash-flow trends. A beta of 1.7239 indicates amplified sensitivity to market swings. Vor Biopharma trades at P/B of 3.14.
Vor Biopharma figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board
Be Your Own Money Manager
Building wealth with Vor Biopharma still requires portfolio discipline because one position merits evaluation by how it improves total return efficiency, not just by its standalone upside. The practical goal is to improve diversification, remove redundancy, and keep return expectations realistic.